Literature DB >> 7494600

Distribution of tangles and threads in the cerebral cortex in progressive supranuclear palsy.

T Hanihara1, N Amano, T Takahashi, H Nagatomo, S Yagashita.   

Abstract

Recent studies have described silver- and tau-positive glia and threads in the degenerating lesions of progressive supranuclear palsy. In this study, Gallyas-Braak silver impregnation and several immunohistochemical techniques were employed to examine the distribution of tangles, abnormal glia and threads in the cerebral cortex of nine cases of progressive supranuclear palsy. In addition to neurofibrillary tangles, argentophilic glia and threads were impregnated exclusively by Gallyas-Braak technique. This technique demonstrated two types of glia profiles: tightly coiled intra-cytoplasmic profiles surrounding nuclei (coiled profiles) and thorn-like profiles with radial ramifications (thorn-like profiles). Thorn-like profiles are possibly in astrocytes and were detected in the cerebral cortex, while coiled profiles are possibly in oligodendroglia and were detected both in the cerebral cortex and subcortical white matter. Topographically, many neurofibrillary tangles were constantly seen in the frontal cortex and in the pre-central gyrus. Numerous neurofibrillary tangles were detected in the entorhinal cortex of the two brains. Argentophilic glia and threads were also frequent both in the frontal cortex and the precentral gyrus; however, they were more frequent in the pre-central gyrus that in the frontal cortex in four of the eight cases examined. In two brains, argentophilic threads were distributed widely in the cerebral cortex and white matter except for the temporal cortex. In immunohistochemical studies, argentophilic glia and threads were mostly positive for Tau 2, and a small number of them were weakly positive for ubiquitin and paired helical filament protein. The immunoproperties of these abnormal glia and threads seemed to be virtually identical to those of neurofibrillary tangles.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494600     DOI: 10.1111/j.1365-2990.1995.tb01066.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

1.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

2.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

3.  β-amyloid triggers ALS-associated TDP-43 pathology in AD models.

Authors:  Alexander M Herman; Preeti J Khandelwal; Brenna B Stanczyk; G William Rebeck; Charbel E-H Moussa
Journal:  Brain Res       Date:  2011-03-02       Impact factor: 3.252

4.  Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy.

Authors:  C Brenneis; K Seppi; M Schocke; T Benke; G K Wenning; W Poewe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

5.  Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells.

Authors:  Steven J Greco; Sraboni Sarkar; Jane M Johnston; Nikolaos Tezapsidis
Journal:  Biochem Biophys Res Commun       Date:  2009-01-21       Impact factor: 3.575

6.  The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.

Authors:  Preeti J Khandelwal; Charbel E-H Moussa
Journal:  Front Psychiatry       Date:  2010-06-03       Impact factor: 4.157

7.  Neuropsychological study of amyotrophic lateral sclerosis and parkinsonism-dementia complex in Kii peninsula, Japan.

Authors:  Akihiro Shindo; Yukito Ueda; Shigeki Kuzuhara; Yasumasa Kokubo
Journal:  BMC Neurol       Date:  2014-07-21       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.